This protocol targets adult patients with Ebola virus disease who have a concurrent bacterial co-infection, presenting at a mild severity level. The presence of bacterial co-infection alongside Ebola virus disease defines a specific clinical sub-population requiring a tailored treatment approach beyond standard supportive care alone.
Management in this setting includes an oral antibiotic course directed at the bacterial co-infection. The complete protocol specifies the agent, dosing schedule, and duration—details that determine how this course is applied in mild disease.